Cardiac safety of simultaneous anti-HER2 and anthracycline therapy

被引：1

作者：

Jafri, Mariam ^{[1
,2
]}

Rea, Daniel ^{[1
,2
,3
]}

机构：

[1] Univ Hosp Birmingham Fdn Trust, Dept Oncol, Mendelsohn Dr, Birmingham, W Midlands, England

[2] Sandwell & West Birmingham NHS Trust, City Hosp, Breast Unit, Dudley Rd, Birmingham, W Midlands, England

[3] Univ Birmingham, Inst Canc & Genom Med, Edgbaston, England

来源：

BREAST CANCER MANAGEMENT | 2016年 / 5卷 / 01期

关键词：

anthracyclines; anti-HER2; agents; cardiac toxicity; neoadjuvant chemotherapy; trastuzumab;

D O I：

10.2217/bmt.16.3

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

A long established oncological dogma requires that trastuzumab should not be given in combination with anthracyclines due to excessive synergistic cardiac morbidity. However, trastuzumab has been recently granted a license in the neoadjuvant setting with concurrent anthracylines. We discuss the role of anti-HER2 agents in breast cancer and their associated toxicities. Anthracycline chemotherapies are a central component of most adjuvant and neoadjuvant breast cancer regimens. Cardiac toxicity due to anthracyclines is explored. Finally, in this article, we will discuss the evidence for concurrent administration of anthracyclines and HER2-targeted agents.

引用

页码：21 / 29

页数：9

共 49 条

[1] Long-Term Cardiac Safety Analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial
Advani, Pooja P.
Ballman, Karla V.
Dockter, Travis J.
Colon-Otero, Gerardo
Perez, Edith A.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (06) : 581 - +
[2] Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials
Albain, K.
Anderson, S.
Arriagada, R.
Barlow, W.
Bergh, J.
Bliss, J.
Buyse, M.
Cameron, D.
Carrasco, E.
Clarke, M.
Correa, C.
Coates, A.
Collins, R.
Costantino, J.
Cutter, D.
Cuzick, J.
Darby, S.
Davidson, N.
Davies, C.
Davies, K.
Delmestri, A.
Di Leo, A.
Dowsett, M.
Elphinstone, P.
Evans, V.
Ewertz, M.
Gelber, R.
Gettins, L.
Geyer, C.
Goldhirsch, A.
Godwin, J.
Gray, R.
Gregory, C.
Hayes, D.
Hill, C.
Ingle, J.
Jakesz, R.
James, S.
Kaufmann, M.
Kerr, A.
MacKinnon, E.
McGale, P.
McHugh, T.
Norton, L.
Ohashi, Y.
Paik, S.
Pan, H. C.
Perez, E.
Peto, R.
Piccart, M.
[J]. LANCET, 2012, 379 (9814) : 432 - 444
[3] Predicting Anthracycline Benefit: TOP2A and CEP17-Not Only but Also
Bartlett, John M. S.
McConkey, Christopher C.
Munro, Alison F.
Desmedt, Christine
Dunn, Janet A.
Larsimont, Denis P.
O'Malley, Frances P.
Cameron, David A.
Earl, Helena M.
Poole, Christopher J.
Shepherd, Lois E.
Cardoso, Fatima
Jensen, Maj-Britt
Caldas, Carlos
Twelves, Christopher J.
Rea, Daniel W.
Ejlertsen, Bent
Di Leo, Angelo
Pritchard, Kathleen I.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15) : 1680 - 1687
[4] Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
Baselga, Jose
Bradbury, Ian
Eidtmann, Holger
Di Cosimo, Serena
de Azambuja, Evandro
Aura, Claudia
Gomez, Henry
Dinh, Phuong
Fauria, Karine
Van Dooren, Veerle
Aktan, Gursel
Goldhirsch, Aron
Chang, Tsai-Wang
Horvath, Zsolt
Coccia-Portugal, Maria
Domont, Julien
Tseng, Ling-Min
Kunz, Georg
Sohn, Joo Hyuk
Semiglazov, Vladimir
Lerzo, Guillermo
Palacova, Marketa
Probachai, Volodymyr
Pusztai, Lajos
Untch, Michael
Gelber, Richard D.
Piccart-Gebhart, Martine
[J]. LANCET, 2012, 379 (9816) : 633 - 640
[5] Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Baselga, Jose
Cortes, Javier
Kim, Sung-Bae
Im, Seock-Ah
Hegg, Roberto
Im, Young-Hyuck
Roman, Laslo
Pedrini, Jose Luiz
Pienkowski, Tadeusz
Knott, Adam
Clark, Emma
Benyunes, Mark C.
Ross, Graham
Swain, Sandra M.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (02) : 109 - 119
[6] Anthracyclines and taxanes in the neo/adjuvant treatment of breast cancer: does the sequence matter?
Bines, J.
Earl, H.
Buzaid, A. C.
Saad, E. D.
[J]. ANNALS OF ONCOLOGY, 2014, 25 (06) : 1079 - 1085
[7] Trastuzumab-Related Cardiotoxicity in Early Breast Cancer: A Cohort Study
Bonifazi, Martina
Franchi, Amatteo
Rossi, Amarta
Moja, Lorenzo
Zambelli, Alberto
Zambon, Antonella
Corrao, Giovanni
La Vecchia, Carlo
Zocchetti, Carlo
Negri, Eva
[J]. ONCOLOGIST, 2013, 18 (07) : 795 - 801
[8] Choosing the Best Trastuzumab-Based Adjuvant Chemotherapy Regimen: Should We Abandon Anthracyclines?
Burstein, Harold J.
Piccart-Gebhart, Martine J.
Perez, Edith A.
Hortobagyi, Gabriel N.
Wolmark, Norman
Albain, Kathy S.
Norton, Larry
Winer, Eric P.
Hudis, Clifford A.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (18) : 2179 - 2182
[9] Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial
Buzdar, Aman U.
Suman, Vera J.
Meric-Bernstam, Funda
Leitch, A. Marilyn
Ellis, Matthew J.
Boughey, Judy C.
Unzeitig, Gary
Royce, Melanie
McCall, Linda M.
Ewer, Michael S.
Hunt, Kelly K.
[J]. LANCET ONCOLOGY, 2013, 14 (13) : 1317 - 1325
[10] Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer
Buzdar, AU
Ibrahim, NK
Francis, D
Booser, DJ
Thomas, ES
Theriault, RL
Pusztai, L
Green, MC
Arun, BK
Giordano, SH
Cristofanilli, M
Frye, DK
Smith, TL
Hunt, KK
Singletary, SE
Sahin, AA
Ewer, MS
Buchholz, TA
Berry, D
Hortobagyi, GN
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 3676 - 3685

← 1 2 3 4 5 →